131030 — Optus Pharmaceutical Co Income Statement
0.000.00%
Last trade - 00:00
- KR₩94bn
- KR₩38bn
- KR₩72bn
- 90
- 75
- 33
- 78
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 60,441 | 60,827 | 57,316 | 58,658 | 72,426 |
Cost of Revenue | |||||
Gross Profit | 36,923 | 38,324 | 32,525 | 31,707 | 41,429 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 45,639 | 45,319 | 46,845 | 53,399 | 64,240 |
Operating Profit | 14,803 | 15,508 | 10,472 | 5,258 | 8,187 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 16,421 | 18,502 | 10,479 | 6,828 | 12,970 |
Provision for Income Taxes | |||||
Net Income After Taxes | 14,596 | 14,405 | 9,892 | 5,012 | 10,760 |
Net Income Before Extraordinary Items | |||||
Net Income | 14,596 | 14,405 | 9,892 | 5,012 | 10,760 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 14,596 | 14,405 | 9,892 | 5,012 | 10,760 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 918 | 893 | 616 | 279 | 692 |
Dividends per Share |